Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR Amyloidosis Cardiomyopathy at the AHA 2018 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
SAN FRANCISCO, Oct. 05, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced that results of its Phase 2 clinical trial studying AG10 in subjects with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM) will be announced in a late-breaking featured science oral presentation at this year’s American Heart Association (AHA) Scientific Sessions.
Daniel Judge, M.D., professor in the division of cardiology at the Medical University of South Carolina, will discuss the data in a presentation entitled “Safety, Tolerability and Transthyretin Stabilization by AG10: A Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients with Transthyretin Amyloid Cardiomyopathy and NYHA Class II/III Heart Failure” as part of the New Trials in Cardiovascular Care oral session at 9:00 AM CT on November 10, 2018.
Eidos will host an investor conference call and webcast following the presentation to highlight details of the Phase 2 data. Details for the call and webcast will be announced at a later date.
AG10 is an investigational, orally-administered small molecule designed to potently stabilize tetrameric transthyretin, or TTR, thereby halting at its outset the series of molecular events that give rise to amyloidosis, or ATTR. AG10 is currently being examined in an open-label extension of a Phase 2 clinical trial in patients with ATTR cardiomyopathy.
AG10 was designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a “rescue mutation” because it has been shown to prevent ATTR in individuals carrying pathogenic, or disease-causing, mutations in the TTR gene. To our knowledge, AG10 is the only TTR stabilizer in development that has been observed to mimic the “super-stabilizing” properties of this rescue mutation.
About Eidos Therapeutics
Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). For more information, please visit www.eidostx.com.